See more : Phoenix Copper Limited (PXCLF) Income Statement Analysis – Financial Results
Complete financial analysis of UniPharma Co., Ltd. (6621.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of UniPharma Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shoei Corporation (9385.T) Income Statement Analysis – Financial Results
- Titan Biotech Limited (TITANBIO.BO) Income Statement Analysis – Financial Results
- Companhia de Gás de São Paulo – COMGÁS (CGAS3.SA) Income Statement Analysis – Financial Results
- Hainan Dadonghai Tourism Centre (Holdings) Co., Ltd. (000613.SZ) Income Statement Analysis – Financial Results
- Avensia AB (publ) (AVEN.ST) Income Statement Analysis – Financial Results
UniPharma Co., Ltd. (6621.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.uni-pharma.com
About UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was incorporated in 1998 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 103.22M | 128.11M | 105.39M | 138.64M | 154.28M |
| Cost of Revenue | 52.21M | 53.49M | 46.06M | 69.32M | 80.53M |
| Gross Profit | 51.02M | 74.62M | 59.33M | 69.32M | 73.75M |
| Gross Profit Ratio | 49.42% | 58.25% | 56.29% | 50.00% | 47.80% |
| Research & Development | 17.83M | 26.32M | 33.05M | 24.86M | 34.83M |
| General & Administrative | 19.94M | 20.30M | 30.27M | 22.01M | 20.19M |
| Selling & Marketing | 40.55M | 48.88M | 36.23M | 43.07M | 46.53M |
| SG&A | 60.49M | 69.18M | 66.50M | 65.07M | 66.72M |
| Other Expenses | 0.00 | 12.63M | -35.32M | -36.13M | 0.00 |
| Operating Expenses | 78.32M | 95.50M | 99.55M | 89.93M | 100.39M |
| Cost & Expenses | 130.53M | 148.98M | 145.61M | 159.25M | 180.91M |
| Interest Income | 1.97M | 1.26M | 1.24M | 1.53M | 1.75M |
| Interest Expense | 14.00K | 39.00K | 99.00K | 141.00K | 163.00K |
| Depreciation & Amortization | 5.55M | 5.53M | 10.79M | 11.17M | 5.68M |
| EBITDA | -16.25M | -1.61M | -63.52M | -44.04M | -13.73M |
| EBITDA Ratio | -15.75% | -1.13% | -60.27% | -31.77% | -14.34% |
| Operating Income | -27.31M | -6.99M | -74.31M | -55.21M | -27.80M |
| Operating Income Ratio | -26.45% | -5.45% | -70.51% | -39.82% | -18.02% |
| Total Other Income/Expenses | 5.49M | 13.85M | -34.19M | -34.74M | 2.76M |
| Income Before Tax | -21.81M | -7.03M | -74.41M | -55.35M | -25.05M |
| Income Before Tax Ratio | -21.13% | -5.49% | -70.60% | -39.93% | -16.23% |
| Income Tax Expense | 0.00 | -581.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -21.81M | -6.45M | -74.41M | -55.35M | -25.05M |
| Net Income Ratio | -21.13% | -5.03% | -70.60% | -39.93% | -16.23% |
| EPS | -0.61 | -0.18 | -2.11 | -1.57 | -0.71 |
| EPS Diluted | -0.61 | -0.18 | -2.11 | -1.57 | -0.71 |
| Weighted Avg Shares Out | 35.50M | 35.49M | 35.20M | 35.20M | 35.22M |
| Weighted Avg Shares Out (Dil) | 35.50M | 35.49M | 35.20M | 35.20M | 35.22M |
Source: https://incomestatements.info
Category: Stock Reports